2009-11-27 08:32:04 -
London, November , 27, 2009
Stockholm, Sweden November 27, 2009 - Biovitrum AB (publ) (STO:BVT)
today announced an agreement with Amgen to expand Biovitrum's Kineret
license to include certain orphan indications. The amended
license provides Biovitrum exclusive rights to develop, manufacture,
market and sell Kineret for these additional orphan indications. In
December 2008, Biovitrum obtained from Amgen the global exclusive
rights to Kineret for rheumatoid arthritis as currently indicated on
its label.
"We are pleased that we now have the opportunity to further develop
the innovative drug Kineret for rare serious diseases and make it
available to additional patients with high unmet medical needs," said
Martin Nicklasson, CEO of Biovitrum. Furthermore, we will be able to
further leverage Kineret product value and the agreement validates
our good and longstanding relationship with Amgen," Nicklasson added.
About Kineret® (anakinra)
Information about Kineret® can be found at the following site:
www.kineretrx.com/
Healthcare professionals should refer to and rely upon the PDR
(Physician's Desk Reference) or the corresponding national labeling
texts.
About Biovitrum
Biovitrum is an international pharmaceutical company that markets
specialist pharmaceuticals in several regions. Using its expertise
and experience Biovitrum takes scientific innovation to patients with
significant unmet medical need. Research expertise and capabilities
are focused on development and production of biotechnology
therapeutics within our prioritized areas of hemophilia,
inflammation/autoimmune diseases, cancer supportive care and
malabsorption. The company has revenues of approximately SEK 1.2
billion and around 400 employees. The company head office is located
in Sweden and it is listed on the Stockholm OMX Nordic Exchange. For
more information please visit www.biovitrum.com.
For further information, please contact
Biovitrum AB (publ)
Erik Kinnman, EVP Investor Relations
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com
Martin Nicklasson, CEO
Phone. +46 8 697 2327
Biovitrum AB (publ) may be required to disclose the information
provided herein pursuant to the Swedish Securities Markets Act. The
information was provided for public release on November 27, 2009 at
8.30 a.m. CET.
hugin.info/134557/R/1357584/330300.pdf
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
